Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement-COVID-19 & Preliminary Statement

23 Mar 2020 17:47

RNS Number : 2844H
Xaar PLC
23 March 2020
 

Xaar plc

 

Trading update and revised date for full year results 

 

Xaar plc ("Xaar" or the "Group"), the leading inkjet printing technology Group, announces a confirmation of previous guidance and a revised date for the presentation of full year results.

 

Full year results

 

Preliminary financial statements for the 12 months ended 31 December 2019 were scheduled to be released 24 March 2020.

 

The FCA has strongly requested all listed companies observe a moratorium on the publication of preliminary financial statements for at least two weeks.

 

In compliance with this request, Xaar will not be releasing preliminary financial statements, but will publish full audited financial statements within four months of the financial year end, subject to any further guidance from the FCA.

 

Trading update

 

Xaar continues to make good progress with its strategy and re-iterates the preliminary guidance for 2019:

 

The Group expects to report revenues for its continuing operations of £49.4 million for the year ended 31 December 2019.

 

Group cash balances (including cash held for investment in Xaar 3D) were £25.3 million at 31 December 2019.

 

COVID19 - Update

 

The health, safety and security of our employees is our upmost priority and appropriate actions have been taken to our operational procedures to mitigate risk.

 

The Group's trading performance in 2020 to date has been in line with expectations. No orders have been cancelled, however we are mindful of the rapidly changing environment in which the business is operating.

 

While the full implications of COVID-19 on the financial performance for the current financial year are difficult to determine at this stage, the Board remains confident in the long-term prospects of the Group.

 

 

Enquiries:

Xaar plc

+44 (0)1223 423 663 

John Mills, Chief Executive Officer

Ian Tichias, Chief Finance Officer

 

 

Tulchan Communications

+44 (0)20 7353 4200

James Macey White

Giles Kernick

Hollie Ralston

 

About XaarXaar is a world leader in the development of digital inkjet technology. Our technology drives the conversion of analogue printing and manufacturing methods to digital inkjet which is more efficient, more economical and more productive than the traditional methods which have been in use for years. We design and manufacture printheads as well as systems for product decoration and industrial 3D Printing which use our inkjet technology. We are the only truly independent inkjet technology company with over 25 years of know how. We offer unrivalled inkjet expertise including technology and printhead design and development and manufacture highly customised product decoration systems and industrial 3D Printing for volume manufacturing. Our unique technologies and products are the leading enabler for innovation and for driving supply chain efficiencies for many industries. Information about Xaar is at www.xaar.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTPPUQCWUPUGMW
Date   Source Headline
21st Sep 20239:57 amRNSHolding(s) in Company
19th Sep 20237:00 amRNS2023 Interim Results
11th Sep 20232:11 pmRNSHolding(s) in Company
11th Sep 202312:14 pmRNSHolding(s) in Company
11th Sep 202312:07 pmRNSHolding(s) in Company
11th Sep 202312:03 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
7th Sep 20239:00 amRNSNotice of 2023 Half Year Results
1st Sep 20239:30 amRNSTotal Voting Rights
25th Aug 202312:13 pmRNSHolding(s) in Company
23rd Aug 202310:24 amRNSHolding(s) in Company
18th Aug 202310:30 amRNSChange of Auditor
17th Aug 202312:55 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSTrading Update
1st Aug 20232:00 pmRNSTotal Voting Rights
28th Jul 20234:30 pmRNSHolding(s) in Company
5th Jul 20239:00 amRNSXaar plc - Commercial partnership with Quantica
4th Jul 20233:00 pmRNSBlock listing Interim Review
3rd Jul 20232:53 pmRNSTotal Voting Rights
1st Jun 202310:37 amRNSTotal Voting Rights
31st May 202311:30 amRNSResult of AGM
31st May 20239:00 amRNSBoard Changes
11th May 20235:41 pmRNSHolding(s) in Company
10th May 20233:10 pmRNSDirector/PDMR Shareholding
2nd May 202312:39 pmRNSTotal Voting Rights
24th Apr 20231:05 pmRNSAnnual Financial Report
3rd Apr 20234:51 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSFinal Results
20th Mar 20232:00 pmRNSNotification of the 2022 Full Year Results Date
1st Mar 20233:19 pmRNSTotal Voting Rights
20th Feb 202312:35 pmRNSHolding(s) in Company
1st Feb 202312:30 pmRNSTotal Voting Rights
30th Jan 202312:30 pmRNSHolding(s) in Company
12th Jan 20237:00 amRNSTrading Update
5th Dec 202210:21 amRNSDirector/PDMR Shareholding
1st Dec 202210:19 amRNSTotal Voting Rights
21st Nov 20224:41 pmRNSSecond Price Monitoring Extn
21st Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20221:38 pmRNSGrant of Sharesave Options
1st Nov 202210:41 amRNSTotal Voting Rights
13th Oct 20222:20 pmRNSHolding(s) in Company
3rd Oct 20224:07 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNS2022 INTERIM RESULTS
1st Sep 20225:32 pmRNSTotal Voting Rights
30th Aug 202210:26 amRNSNotice of 2022 Half Year Results
1st Aug 20224:33 pmRNSTotal Voting Rights
1st Aug 202211:25 amRNSHolding(s) in Company
14th Jul 20227:00 amRNSTrading Update
1st Jul 20221:14 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.